Clinical trials: the Diabetic Process
Type 2 Diabetes Mellitus, Atherosclerosis
Effects of 5-day Statin Withdrawal on Endothelial Progenitor Cells and Inflammatory Markers in Type 2 Diabetic Patients
Statins are commonly prescribed to lower cardiovascular risk in primary and secondary prevention. Despite their well known efficacy, statin withdrawal is a common event.
- Conditions
- Type 2 Diabetes Mellitus, Atherosclerosis, Dyslipidemia
- Trial name
- SStatin-EPC (NCT01600690)
- Testing
- Statin withdrawal
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- University of Padova
Diabetic Foot Ulcer, Diabetes Mellitus
Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers
The aim of this study is to evaluate the therapeutic efficacy of uncultured adipose derived stromal vascular fraction (SVF) and cultured adipose derived stem cells (ASCs) both supplemented with platelet rich plasma (PRP) to treat…
- Conditions
- Diabetic Foot Ulcer, Diabetes Mellitus, Diabetic Foot, Diabetic Foot Infection
- Trial name
- NCT05610865
- Testing
- Control; Standard-of-care management, Only PRP injection, PRP + SVF injection
- Where
- Pakistan
- Volunteers
- 28 people
- Sponsor
- University of the Punjab
the Diabetic Process
Deacylated Ghrelin and Beta Cell Function
Use of human unacylated ghrelin (UAG, also called des-octanoyl ghrelin) to study physiology in healthy subjects. The proposed research is an investigator-initiated study funded by the National Institutes of Health designed to…
- Trial name
- UAG (NCT01531283)
- Testing
- unacylated ghrelin, acyl ghrelin, combined acyl and desacyl ghrelin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- David Dalessio
Diabetic Foot
Autologous Micro-fragmented Adipose Tissue in the Treatment of Minor Amputations of Diabetic Foot
This is a randomized controlled monocentric study on 114 diabetic patients with the aim of evaluating the efficacy of the lipofilling with Lipogems® system in diabetic patients that are candidates for a minor amputation in the…
- Trial name
- NCT03276312
- Testing
- Lipogems
- Where
- Italy
- Volunteers
- 112 people
- Sponsor
- University of Modena and Reggio Emilia
Erectile Dysfunction Associated With Type 2 Diabetes Mellitus
Efficacy of Wharton Jelly in Erectile Dysfunction
Efficacy of Intracavernous injection of Wharton jelly Mesenchymal stem cells for the treatment of erectile dysfunction in diabetic patients.
- Trial name
- NCT03751735
- Testing
- Wharton Jelly Mesenchymal stem cells
- Where
- Jordan
- Volunteers
- 9 people
- Sponsor
- Sophia Al-Adwan
Ketoacidosis, Diabetic
Allogeneic Umbilical Cord Mesenchymal Stem Cell Transplantation for Type 1 Diabetes With Diabetic Ketoacidosis
This is a phase II trial in individuals who have been diagnosed with type 1 diabetes within the previous 12 months and suffered from diabetic ketoacidosis at onset of disease.
- Trial name
- UCMSCDKA (NCT02763423)
- Testing
- umbilical cord mesenchymal stem cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Type1diabetes
Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function
To evaluate the safety and efficacy of Stem cells from human exfoliated teeth transplantation in patients with Islet function decreased significantly to provides scientific basis for further clinical studies to verify the safety…
- Trial name
- NCT03912480
- Testing
- Stem cells from human exfoliated teeth
- Where
- China
- Volunteers
- 24 people
- Sponsor
- CAR-T (Shanghai) Biotechnology Co., Ltd.
Diabetic Nephropathy
Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy
Diabetic nephropathy (DN) is one of the most serious complications of diabetes and the leading cause of end-stage chronic kidney disease. DN is a refractory disease with low awareness, high incidence, and high disability.
- Trial name
- UC-MSCs (NCT04562025)
- Testing
- UC-MSCs
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Renmin Hospital of Wuhan University
Diabetic Peripheral Neuropathy Type 2
Treatment With Human Umbilical Cord Mesenchymal Stem Cells for Refractory Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy (DPN) is one of the most common chronic complications in type 2 diabetes, conventional drug therapy can only target a single pathogenesis but not treat Diabetic Peripheral Neuropathy (DPN)…
- Trial name
- NCT05507697
- Testing
- HUC-MSCs, Lipoic Acid
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Wuhan Central Hospital
Chronic Limb-threatening Ischemia, Diabetes Mellitus
Bone Marrow Mononuclear Cells vs Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb Ischemia
Patients in the severe stages of Chronic limb-threatening ischemia (CLTI) are prone to amputation and death, leading to poor quality of life and a great socioeconomic burden.
- Trial name
- NCT05631444
- Testing
- Cell-based therapy
- Where
- Colombia
- Volunteers
- 24 people
- Sponsor
- Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle
Diabetic Wounds, Venous Stasis Wounds
The Role of Lipoaspirate Injection in the Treatment of Diabetic Lower Extremity Wounds and Venous Stasis Ulcers
A prospective, single blinded randomized clinical study will be performed to determine if the injection of lipoaspirate into diabetic or venous stasis wounds promotes wound healing or wound closure at a faster rate than…
- Trial name
- NCT00815217
- Testing
- injection of lipoaspirate, control
- Where
- United States
- Sponsor
- Washington D.C. Veterans Affairs Medical Center
Diabetic Foot Ulcer
Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System in the Healing of Diabetic Foot Ulcers
This is a randomized controlled multi center study on diabetic patients with the aim of evaluating the efficacy of the adipose tissue processed with the SyntrFuge™ system in diabetic patients with diabetic foot ulcers.
- Trial name
- NCT05519501
- Testing
- Syntrfuge Microfragmented Fat, Standard of Care
- Volunteers
- 62 people
- Sponsor
- Syntr Health Technologies, Inc.
Erectile Dysfunction Associated With Type 2 Diabetes Mellitus
Safety of Wharton Jelly in Erectile Dysfunction
Safety of Intracavernous injection of Wharton jelly Mesenchymal stem cells for the treatment of erectile dysfunction in diabetic patients.
- Trial name
- NCT02945449
- Testing
- Wharton Jelly Mesenchymal stem cells
- Where
- Jordan
- Volunteers
- 9 people
- Sponsor
- Sophia Al-Adwan
Wounds, Diabetic Foot Ulcers
Safety and Exploratory Efficacy Study of Collagen Membrane With Mesenchymal Stem Cells in the Treatment of Skin Defects
The purpose of the present study is to evaluate the safety and exploratory efficacy of the medical collagen membrane with umbilical cord derived mesenchymal stem cells in the treatment of patients with skin defects.
- Conditions
- Wounds, Diabetic Foot Ulcers, Burns
- Trial name
- SEESCMMSCTSD (NCT02672280)
- Testing
- Medical Collagen Membrane with MSC, Medical Collagen Membrane
- Volunteers
- 30 people
- Sponsor
- South China Research Center for Stem Cell and Regenerative Medicine
Diabetic Neuropathic Ulcer
Allogeneic ABCB5-positive Stem Cells for Treatment of DFU "Malum Perforans"
The aim of this clinical trial is to investigate the efficacy (by monitoring the wound surface area reduction of Diabetic Foot Ulcers) and safety (by monitoring adverse events) of two doses of the allogeneic investigational…
- Trial name
- NCT03267784
- Testing
- allo-APZ2-DFU
- Where
- 7 sites in Germany
- Volunteers
- 23 people
- Sponsor
- RHEACELL GmbH & Co. KG
Urologic Diseases, Erectile Dysfunction With Diabetes Mellitus
The Outcomes of Intracavernosal Umbilical Cord Mesenchymal Stem Cells Implantation in Patients With Diabetic Erectile Dysfunction
Erectile dysfunction (ED) is a complex condition affecting men worldwide. Diabetes mellitus (DM) is one of the most common causes of ED. The prevalence of ED in DM varies around 35-85%.
- Trial name
- NCT04972890
- Testing
- stem cells
- Where
- Indonesia
- Volunteers
- 12 people
- Sponsor
- Universitas Indonesia
Critical Limb Ischemia, Arteriosclerosis Obliterans
Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia
Adipose-derived regenerative cells (ADRC) will be extracted from lipoaspirate by enzymatic digestion. 10 mL of autologous ADRC suspension injected intramuscularly, close to the site of muscle injury.
- Conditions
- Critical Limb Ischemia, Arteriosclerosis Obliterans, Peripheral Arterial Disease, Thromboangiitis Obliterans
- Trial name
- NCT02864654
- Testing
- ADRC injection, ADRC isolation, Liposuction
- Where
- Russia
- Volunteers
- 9 people
- Sponsor
- Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
Diabetic Foot
Induced Wound Healing by Application of Expanded Bone Marrow Stem Cells in Diabetic Patients With Critical Limb Ischemia
Diabetic foot patients with chronic limb ischemia and without the option for surgical or interventional revascularization were recruited and randomized to the transplant groups or the control group within this clinical trial.
- Trial name
- NCT01065337
- Testing
- tissue repair cells (TRC), bone marrow stem cells (BMC)
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Ruhr University of Bochum
Diabetic Foot Ulcer
Safety and Efficacy of Stem Cells for Diabetic Foot Ulcer
The objective of this clinical trial is to evaluate the effectiveness and safety of Wharton-Jelly mesenchymal stem cells administered around the ulcer site in patients with nonhealing diabetic foot ulcers.
- Trial name
- NCT06231771
- Testing
- Allogeneic mesenchymal stem cells (MSCs), Normal Saline
- Volunteers
- 22 people
- Sponsor
- Supergenics Life Science Sdn. Bhd.
Diabetic Foot Ulcer (DFU), Exosomes
Efficacy and Safety of Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes in the Treatment of Diabetic Foot Ulcers: A Double-blinded Randomized Controlled Clinical Trial
Study effeciency and safety of WJ-MSC derived exosomes in DFU healing
- Trial name
- WJ-MSC (NCT06812637)
- Testing
- WJ-MSC- Exosomes, SOC (Standard of care)
- Where
- Egypt
- Volunteers
- 110 people
- Sponsor
- Kafrelsheikh University